Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,029.00+0.35%ETH$2,411.21+0.14%GOLD$4,306.30-1.85%OIL$102.01-0.41%
Smart Investors Daily
CB

NASDAQ · CBIO

Crescent Biopharma, Inc. Common Stock

Healthcare · Biotechnology

$18.80

Down-$1.62 (-8.62%)

Updated Sep 16, 2026, 11:30 PM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
213.67M
P/E ratio
-45.46
Dividend yield
0.00%
52-week range
$8.72 – $27.41
Volume
357.96K
Avg. volume
143.92K

Price performance

CBIO price history

1M range · 20 trading sessions · Daily adjusted prices

CBIO closed at $18.80 after 20 trading sessions, up 12.64% for the selected period.

Last close
$18.80
Period change
+12.64%
Period low
$16.23
Period high
$20.88
Daily close
View OHLC price history
CBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$19.60$20.305$18.40$18.80357.96K
Sep 14, 2026$19.50$20.40$19.40$19.68251.18K
Sep 11, 2026$19.81$20.35$19.11$19.41264.45K
Sep 10, 2026$19.65$19.895$19.16$19.46233.14K
Sep 9, 2026$20.30$20.91$19.92$19.99296.01K
Sep 8, 2026$20.58$21.19$19.91$20.46647.21K
Sep 4, 2026$20.09$21.53$20.09$20.88239.7K
Sep 3, 2026$18.73$22.33$18.73$20.40773.53K
Sep 2, 2026$18.00$19.01$17.93$18.54214.87K
Sep 1, 2026$16.43$18.13$16.29$17.93788.17K
Aug 31, 2026$17.65$17.65$16.14$16.60163K
Aug 28, 2026$17.78$18.00$17.02$17.75149.15K
Aug 27, 2026$17.89$18.255$17.50$17.7676.87K
Aug 26, 2026$16.94$18.47$16.94$18.02317.59K
Aug 25, 2026$17.12$17.66$16.87$17.00129.69K
Aug 24, 2026$17.21$17.5099$16.79$16.97131.54K
Aug 21, 2026$16.39$17.19$16.03$17.15218.39K
Aug 20, 2026$17.13$17.13$16.055$16.23124.8K
Aug 19, 2026$17.14$17.495$16.59$17.32170.24K
Aug 18, 2026$17.34$17.76$16.36$16.69169.61K

Latest CBIO news

The latest Smart Investors Daily articles mentioning CBIO.

Stock researchCompany · Overview

CBIO research

Overview

Company profile and research snapshot.

Company profile

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.00
Implied upside
—
Analysts
—
CBIO recent ratings
DateFirmRatingTarget
Sep 14, 2026WedbushOutperform—
Aug 27, 2026WedbushOutperform—
Jun 1, 2026HC Wainwright & Co.Neutral—
Mar 2, 2026HC Wainwright & Co.Buy—
Jan 21, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Crescent Biopharma to Present at September Investor Conferences

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September: 2026 Cantor Global Healthcare Conference, fireside chat on Thursday, September 10, 2026 at 1:35 p.m. ET in New York.Morgan Stanley 24th Annual Global He

Benzinga · Jul 30, 2026

Crescent Biopharma Q2 EPS $(0.74) Beats $(0.79) Estimate

Crescent Biopharma (NASDAQ:CBIO) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.79) by 6.33 percent. This is a 84.99 percent increase over losses of $(4.93) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By